# Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients

> **NCT00711958** · PHASE3 · COMPLETED · sponsor: **Sandoz** · enrollment: 114 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** HX575, solution for injection (s.c.)
- **DRUG:** ERYPO®, Janssen-Cilag, solution for injection (s.c.)

## Key facts

- **NCT ID:** NCT00711958
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-07
- **Final completion:** 2005-12
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2017-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00711958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00711958, "Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00711958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*